Brain Tumor Protocol List

March 2021

Aflac Cancer & Blood Disorders Center
CHILDREN'S HEALTHCARE OF ATLANTA

Ependymoma treatment protocols			
Study	**Clinical trial name**	**Phase/type**	**Age**
Indoximod GCC1949	GCC1949: Phase 2 trial of indoximod with chemotherapy and radiation for children with progressive brain tumors or newly diagnosed DIPG https://clinicaltrials.gov/ct2/show/NCT04049669	II	>3 to <22 yr
AflacST1502 CHOANOME II	AflacST1502: A Phase II Study of Sirolimus in Combination with Metronomic Chemo-therapy in Children with Recurrent and/or Refractory Solid and CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02574728	II	>12 mo to ≤30 yr
COG ADVL1823	ADVL1823, Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias https://clinicaltrials.gov/ct2/show/NCT03834961	II	≤30 yr
COG APEC1621A[REQ]	APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions https://clinicaltrials.gov/ct2/show/NCT03213704	II	≥12 mo to ≤21 yr
COG APEC1621B[REQ]	APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Relapsed Pediatric Solid Tumors Harboring FGFR1/2/3/4 Alterations https://clinicaltrials.gov/ct2/show/NCT03210714	II	≥12 mo to ≤21 yr
COG APEC1621C[REQ]	APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex https://clinicaltrials.gov/ct2/show/NCT03213665	II	≥12 mo to ≤21 yr
COG APEC1621D[REQ]	APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03213678	II	≥12 mo to ≤21 yr
COG APEC1621F[REQ]	APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations https://clinicaltrials.gov/ct2/show/NCT03213652	II	≥12 mo to ≤21 yr
COG APEC1621G[REQ]	APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Actionable BRAF V600 Mutations https://clinicaltrials.gov/ct2/show/NCT03220035	II	≥12 mo to ≤21 yr

COG APEC1621H[REQ]	APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes https://clinicaltrials.gov/ct2/show/NCT03233204	II	≥12 mo to ≤21 yr
COG APEC1621I[REQ]	APEC1621I NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes https://clinicaltrials.gov/ct2/show/NCT03526250	II	≥12 mo to ≤21 yr
COG APEC1621J[REQ]	APEC1621J NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations https://clinicaltrials.gov/ct2/show/NCT03698994	II	≥12 mo to ≤21 yr
Ignyta RXDX-101-03	A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02650401	I/Ib	≥2 to <22 yr
LOXO-EXT-17005	LOXO-EXT-17005: A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers https://clinicaltrials.gov/ct2/show/NCT02650401	I/II	≥1 mo
AflacST1501	Aflac ST1501, A Phase I Study of Abemaciclib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and in Children with Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors https://clinicaltrials.gov/ct2/show/NCT02644460	I	≥2 to ≤25 yr
PBTC-045	PBTC-045: A Safety and Preliminary Efficacy trial of MK-3475 (pembrolizumab; anti-PD-1) in Children with Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-brainstem High-grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma and Hypermutated Brain Tumors https://clinicaltrials.gov/ct2/show/NCT02359565	I	≥1 to ≤18 yr
PBTC-048	PBTC-048: Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-grade Glioma and Ependymoma	I	≥5 to ≤21 yr
PBTC-051	Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/ Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma https://clinicaltrials.gov/ct2/show/NCT03389802	I	≥1 to ≤21 yr

COG ADVL1615	ADVL1615, A Phase 1 Study of Pevonedistat (MLN4924 IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/showNCT03323034	I	Part A1: ≥12 mo to ≤21 yr Part A2: ≥6 mo to <12 mo
COG ADVL1921	Phase 1 Study to Evaluate the Safety and Phrmacokinetics of Palbociclib (Ibrance®) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03709680	I	≥2 to <21 yr
Ependymoma supportive treatment and non-therapeutic protocols			
Study	**Clinical trial name**	**Phase/type**	**Age**
AflacPM1702	Aflac Precision Medicine Program (APMP) Study	Non-therapeutic	<30 yr
COG APEC14B1	APEC14B1: The Project:Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study https://clinicaltrials.gov/ct2/show/NCT02402244	Non-therapeutic	≤25 yr
COG APEC1621SC	APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol https://clinicaltrials.gov/ct3/show/NCT03155620	NA	≥12 mo to ≤21 yr
COG ALTE03N1	Key Adverse Events after Childhood Cancer (cardiac, stroke, secondary malig)/closed to AVN patients as of 11-26-08 https://clinicaltrials.gov/ct2/show/NCT00082745	Non-therapeutic	≤21 yr at dx
COG ALTE05N1	Umbrella Long-Term Follow-Up Protocol https://clinicaltrials/gov/ct2/show/NCT00736749	Non-therapeutic	All ages
QOL Targeted Tx Brain Tumors	Health-related Quality of Life Outcomes during Molecularly Targeted Therapy for the Treatment of High Risk Pediatric Brain Tumors	Non-therapeutic	≤21 yr
Telehealth Home-based Transition	Development and Pilot of a Telehealth Home-based Transition Intervention for Pediatric and Young Adults with Cancer	Non-therapeutic	≤29 yr
Germ cell tumor treatment protocols			
Study	**Clinical trial name**	**Phase/type**	**Age**
Indoximod GCC1949	GCC1949: Phase 2 trial of indoximod with chemotherapy and radiation for children with progressive brain tumors or newly diagnosed DIPG https://clinicaltrials.gov/ct2/show/NCT04049669	II	>3 to <22 yr
COG ADVL1823	ADVL1823, Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias https://clinicaltrials.gov/ct2/show/NCT03834961	II	≤30 yr

COG APEC1621A[REQ]	APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions https://clinicaltrials.gov/ct2/show/NCT03213704	II	≥12 mo to ≤21 yr
COG APEC1621B[REQ]	APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Relapsed Pediatric Solid Tumors Harboring FGFR1/2/3/4 Alterations https://clinicaltrials.gov/ct2/show/NCT03210714	II	≥12 mo to ≤21 yr
COG APEC1621C[REQ]	APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex https://clinicaltrials.gov/ct2/show/NCT03213665	II	≥12 mo to ≤21 yr
COG APEC1621D[REQ]	APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03213678	II	≥12 mo to ≤21 yr
COG APEC1621F[REQ]	APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations https://clinicaltrials.gov/ct2/show/NCT03213652	II	≥12 mo to ≤21 yr
COG APEC1621G[REQ]	APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Actionable BRAF V600 https://clinicaltrials.gov/ct2/show/NCT03220035	II	≥12 mo to ≤21 yr
COG APEC1621H[REQ]	APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes https://clinicaltrials.gov/ct2/show/NCT03233204	II	≥12 mo to ≤21 yr
COG APEC1621I[REQ]	APEC1621I NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes https://clinicaltrials.gov/ct2/show/NCT03526250	II	≥12 mo to ≤21 yr
COG APEC1621J[REQ]	APEC1621J NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations https://clinicaltrials.gov/ct2/show/NCT03698994	II	≥12 mo to ≤21 yr
Ignyta RXDX-101-03	A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02650401	I/Ib	≥2 to <22 yr

LOXO-EXT-17005	LOXO-EXT-17005: A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers https://clinicaltrials.gov/ct2/show/NCT03215511	I/II	≥1 mo
COG ADVL1514	ADVL1514, A Phase 1 Study of ABI-009 (Nab-Rapamycin) (IND# 133537) in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan https://clinicaltrials.gov/ct2/show/NCT02975882	I	≥12 mo to ≤21 yr
COG ADVL1615	ADVL1615, A Phase 1 Study of Pevonedistat (MLN4924 IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03323034	I	Part A1: ≥12 mo to ≤21 yr Part A2: ≥6 mo to <12 mo
COG ADVL1921	Phase 1 Study to Evaluate the Safety and Phrmacokinetics of Palbociclib (Ibrance®) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03709680	I	≥2 to <21 yr
AflacST1501	Aflac ST1501, A Phase I Study of Abemaciclib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and in Children with Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors https://clinicaltrials.gov/ct2/show/NCT02644460	I	≥2 to ≤25 yr
PBTC-051	Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/ Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma https://clinicaltrials.gov/ct2/show/NCT03389802	I	≥1 to ≤21 yr
Germ cell supportive treatment and non-therapeutic protocols			
Study	**Clinical trial name**	**Phase/type**	**Age**
AflacPM1702	Aflac Precision Medicine Program (APMP) Study	Non-therapeutic	<30 yr
COG APEC14B1	APEC14B1: The Project:Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study https://clinicaltrials.gov/ct2/show/NCT02402244	Non-therapeutic	≤25 yr
APEC1621SC	APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol https://clinicaltrials.gov/ct2/show/NCT03155620	NA	≥12 mo to ≤21 yr
COG ALTE03N1	Key Adverse Events after Childhood Cancer (cardiac/stroke/secondary malig)/closed to AVN patients as of 11-26-08 https://clinicaltrials.gov/ct2/show/NCT00082745	Non-therapeutic	≤21 yr at dx

COG ALTE05N1	Umbrella Long-Term Follow-Up Protocol https://clinicaltrials.gov/ct2/show/NCT00736749	Non-therapeutic	All ages
QOL Targeted Tx Brain Tumors	Health-related Quality of Life Outcomes during Molecularly Targeted Therapy for the Treatment of High-Risk Pediatric Brain Tumors	Non-therapeutic	≤21 yr
Telehealth Home-based Transition	Development and Pilot of a Telehealth Home-based Transition Intervention for Pediatric and Young Adults with Cancer	Non-therapeutic	≤29 yr
Low-grade glioma treatment protocols			
Study	**Clinical trial name**	**Phase/type**	**Age**
COG ACNS1831	ACNS1831: A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/ Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG) https://clinicaltrials.gov/ct2/show/NCT03871257	III	≥2 to ≤21 yr
COG ACNS1833	ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) https://clinicaltrials.gov/ct2/show/NCT04166409	III	≥2 to ≤21 yr
Indoximod GCC1949	GCC1949: Phase 2 trial of indoximod with chemotherapy and radiation for children with progressive brain tumors or newly diagnosed DIPG https://clinicaltrials.gov/ct2/show/NCT04049669	II	>3 to <22 yr
AflacST1502 CHOANOME II	AflacST1502: A Phase II Study of Sirolimus in Combination with Metronomic Chemo-therapy in Children with Recurrent and/or Refractory Solid and CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02574728	II	>12 mo to ≤30 yr
OZM-063	A Phase II, Open-labeled, Multi-center, Randomized Controlled Trial of Vinblastine +/- Bevacizumab for the Treatment of Chemotherapy-naïve Children with Unresectable or Progressive Low Grade Glioma	II	6 mo to <18 yr
COG ADVL1823	ADVL1823, Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias https://clinicaltrials.gov/ct2/show/NCT03834961	II	≤30 yr
COG APEC1621A[REQ]	APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions https://clinicaltrials.gov/ct2/show/NCT03213704	II	≥12 mo to ≤21 yr

COG APEC1621B[REQ]	APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Relapsed Pediatric Solid Tumors Harboring FGFR1/2/3/4 Alterations https://clinicaltrials.gov/ct2/show/NCT03210714	II	≥12 mo to ≤21 yr
COG APEC1621C[REQ]	APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex https://clinicaltrials.gov/ct2/show/NCT03213665	II	≥12 mo to ≤21 yr
COG APEC1621D[REQ]	APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03213678	II	≥12 mo to ≤21 yr
COG APEC1621F[REQ]	APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations https://clinicaltrials.gov/ct2/show/NCT03213652	II	≥12 mo to ≤21 yr
COG APEC1621G[REQ]	APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Actionable BRAF V600 Mutations https://clinicaltrials.gov/ct2/show/NCT03220035	II	≥12 mo to ≤21 yr
COG APEC1621H[REQ]	APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes https://clinicaltrials.gov/ct2/show/NCT03233204	II	≥12 mo to ≤21 yr
COG APEC1621I[REQ]	APEC1621I NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes https://clinicaltrials.gov/ct2/show/NCT03526250	II	≥12 mo to ≤21 yr
COG APEC1621J[REQ]	APEC1621J NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations https://clinicaltrials.gov/ct2/show/NCT03698994	II	≥12 mo to ≤21 yr
Ignyta RXDX-101-03	A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02650401	I/Ib	≥2 to <22 yr
LOXO-EXT-17005	LOXO-EXT-17005: A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers https://clinicaltrials.gov/ct2/show/NCT03215511	I/II	≥1 mo

PBTC-055	PBTC-055: Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Refractory Gliomas in Children and Young Adults https://clinicaltrials.gov/ct2/show/NCT04201457	I/II	≥1 to ≤30 yr
COG ADVL1514	ADVL1514, A Phase 1 Study of ABI-009 (Nab-Rapamycin) (IND# 133537) in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan https://clinicaltrials.gov/ct2/show/NCT02975882	I	≥12 mo to ≤21 yr
COG ADVL1615	ADVL1615, A Phase 1 Study of Pevonedistat (MLN4924 IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03323034	I	Part A1: ≥12 mo to ≤21 yr Part A2: ≥6 mo to <12 mo
COG ADVL1921	Phase 1 Study to Evaluate the Safety and Phrmacokinetics of Palbociclib (Ibrance®) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03709680	I	≥2 to <21 yr
AflacST1501	Aflac ST1501, A Phase I Study of Abemaciclib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and in Children with Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors https://clinicaltrials.gov/ct2/show/NCT02644460	I	≥2 to ≤25 yr
PBTC-051	Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/ Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma https://clinicaltrials.gov/ct2/show/NCT03389802	I	≥1 to ≤21 yr

High-grade glioma treatment protocols			
Study	**Clinical trial name**	**Phase/type**	**Age**
Indoximod GCC1949	GCC1949: Phase 2 trial of indoximod with chemotherapy and radiation for children with progressive brain tumors or newly diagnosed DIPG https://clinicaltrials.gov/ct2/show/NCT04049669	II	>3 to <22 yr
PEG-Intron	A Phase II Study of Pegylated Interferon ALFA-2b in Children with Recurrent or Refractory and Radiographically or Clinically Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas https://clinicaltrials.gov/ct2/show/NCT02343224	II	>3 to <25 yr
AflacST1502 CHOANOME II	AflacST1502: A Phase II Study of Sirolimus in Combination with Metronomic Chemo-therapy in Children with Recurrent and/or Refractory Solid and CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02574728	II	>12 mo to ≤30 yr
COG APEC1621A[REQ]	APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions https://clinicaltrials.gov/ct2/show/NCT03213704	II	≥12 mo to ≤21 yr
COG APEC1621B[REQ]	APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Relapsed Pediatric Solid Tumors Harboring FGFR1/2/3/4 Alterations https://clinicaltrials.gov/ct2/show/NCT03210714	II	≥12 mo to ≤21 yr
COG APEC1621C[REQ]	APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex https://clinicaltrials.gov/ct2/show/NCT03213665	II	≥12 mo to ≤21 yr
COG APEC1621D[REQ]	APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03213678	II	≥12 mo to ≤21 yr
COG APEC1621F[REQ]	APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations https://clinicaltrials.gov/ct2/show/NCT03213652	II	≥12 mo to ≤21 yr
COG APEC1621G[REQ]	APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Actionable BRAF V600 Mutations https://clinicaltrials.gov/ct2/show/NCT03220035	II	≥12 mo to ≤21 yr

COG APEC1621H[REQ]	APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes https://clinicaltrials.gov/ct2/show/NCT03233204	II	≥12 mo to ≤21 yr
COG APEC1621I[REQ]	APEC1621I NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes https://clinicaltrials.gov/ct2/show/NCT03526250	II	≥12 mo to ≤21 yr
COG APEC1621J[REQ]	APEC1621J NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations https://clinicaltrials.gov/ct2/show/NCT03698994	II	≥12 mo to ≤21 yr
COG ACNS1721[REQ]	ACNS1721: A Phase 2 Study of Veliparib (ABT-888, IND# 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations https://clinicaltrials.gov/ct2/show/NCT03581292	II	≥3 to ≤25 yr
COG ACNS1723[REQ]	ACNS1723, A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355) https://clinicaltrials.gov/ct2/show/NCT03919071	II	≥3 to ≤21 yr
Ignyta RXDX-101-03	A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02650401	I/Ib	≥2 to <22 yr
LOXO-EXT-17005	LOXO-EXT-17005: A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers https://clinicaltrials.gov/ct2/show/NCT03215511	I/II	≥1 mo
PBTC-055	PBTC-055: Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Refractory Gliomas in Children and Young Adults https://clinicaltrials.gov/ct2/show/NCT04201457	I/II	≥1 to ≤30 yr
AflacST1501	Aflac ST1501, A Phase I Study of Abemaciclib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and in Children with Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors https://clinicaltrials.gov/ct2/show/NCT02644460	I	≥2 to ≤25 yr

PBTC-045	PBTC-045: A Safety and Preliminary Efficacy trial of MK-3475 (pembrolizumab; anti-PD-1) in Children with Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-brainstem High-grade Gliomas (NB-HGG), Ependymoma, Medullo-blastoma and Hypermutated Brain Tumors https://clinicaltrials.gov/ct2/show/NCT02359565	I	≥1 to ≤18 yr
PBTC-048	PBTC-048: Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-grade Glioma and Ependymoma	I	≥5 to ≤21 yr
PBTC-051	Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/ Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma https://clinicaltrials.gov/ct2/show/NCT03389802	I	≥1 to ≤21 yr
ONC014	ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent Pediatric H3 K27M Gliomas https://clinicaltrials.gov/ct2/show/NCT03416530	I	≥2 to <19 yr
COG ADVL1615	ADVL1615, A Phase 1 Study of Pevonedistat (MLN4924 IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03323034	I	Part A1: ≥12 mo to ≤21 yr Part A2: ≥6 mo to <12 mo
COG ADVL1921	Phase 1 Study to Evaluate the Safety and Phrmacokinetics of Palbociclib (Ibrance®) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03709680	I	≥2 to <21 yr
Intrinsic pontine glioma treatment protocols			
Study	**Clinical trial name**	**Phase/type**	**Age**
Indoximod GCC1949	GCC1949: Phase 2 trial of indoximod with chemotherapy and radiation for children with progressive brain tumors or newly diagnosed DIPG https://clinicaltrials.gov/ct2/show/NCT04049669	II	>3 to <22 yr
AflacST1502 CHOANOME II	AflacST1502: A Phase II Study of Sirolimus in Combination with Metronomic Chemo-therapy in Children with Recurrent and/or Refractory Solid and CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02574728	II	>12 mo to ≤30 yr
COG ADVL1823	ADVL1823, Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias https://clinicaltrials.gov/ct2/show/NCT03834961	II	≤30 yr

COG APEC1621A[REQ]	APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions https://clinicaltrials.gov/ct2/show/NCT03213704	II	≥12 mo to ≤21 yr
COG APEC1621B[REQ]	APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Relapsed Pediatric Solid Tumors Harboring FGFR1/2/3/4 Alterations https://clinicaltrials.gov/ct2/show/NCT03210714	II	≥12 mo to ≤21 yr
COG APEC1621C[REQ]	APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex https://clinicaltrials.gov/ct2/show/NCT03213665	II	≥12 mo to ≤21 yr
COG APEC1621D[REQ]	APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03213678	II	≥12 mo to ≤21 yr
COG APEC1621F[REQ]	APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations https://clinicaltrials.gov/ct2/show/NCT03213652	II	≥12 mo to ≤21 yr
COG APEC1621G[REQ]	APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Actionable BRAF V600 Mutations https://clinicaltrials.gov/ct2/show/NCT03220035	II	≥12 mo to ≤21 yr
COG APEC1621H[REQ]	APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes https://clinicaltrials.gov/ct2/show/NCT03233204	II	≥12 mo to ≤21 yr
COG APEC1621I[REQ]	APEC1621I NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes https://clinicaltrials.gov/ct2/show/NCT03526250	II	≥12 mo to ≤21 yr
COG APEC1621J[REQ]	APEC1621J NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations https://clinicaltrials.gov/ct2/show/NCT03698994	II	≥12 mo to ≤21 yr

Ignyta RXDX-101-03	A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02650401	I/Ib	≥2 to <22 yr
LOXO-EXT-17005	LOXO-EXT-17005: A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers https://clinicaltrials.gov/ct2/show/NCT03215511	I/II	≥1 mo
PBTC-045	PBTC-045: A Safety and Preliminary Efficacy trial of MK-3475 (pembrolizumab; anti-PD-1) in Children with Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-brainstem High-grade Gliomas (NB-HGG), Ependymoma, Medullo-blastoma and Hypermutated Brain Tumors https://clinicaltrials.gov/ct2/show/NCT02359565	I	≥1 to ≤18 yr
COG ADVL1416	ADVL1416, A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02564198	I	≥12 mo to ≤21 yr
COG ADVL1514	ADVL1514, A Phase 1 Study of ABI-009 (Nab-Rapamycin) (IND# 133537) in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan https://clinicaltrials.gov/ct2/show/NCT02975882	I	≥12 mo to ≤21 yr
COG ADVL1615	ADVL1615, A Phase 1 Study of Pevonedistat (MLN4924 IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03323034	I	Part A1: ≥12 mo to ≤21 yr Part A2: ≥6 mo to <12 mo
COG ADVL1921	Phase 1 Study to Evaluate the Safety and Phrmacokinetics of Palbociclib (Ibrance®) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03709680	I	≥2 to <21 yr
AflacST1501	Aflac ST1501, A Phase I Study of Abemaciclib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and in Children with Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors https://clinicaltrials.gov/ct2/show/NCT02644460	I	≥2 to ≤25 yr
ONC014	ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent Pediatric H3 K27M Gliomas https://clinicaltrials.gov/ct2/show/NCT03416530	I	≥2 to <19 yr

PBTC-051	Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/ Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma https://clinicaltrials.gov/ct2/show/NCT03389802	I	≥1 to ≤21 yr
Glioma supportive treatment and non-therapeutic protocols			
Study	**Clinical trial name**	**Phase/type**	**Age**
AflacPM1702	Aflac Precision Medicine Program (APMP) Study	Non-therapeutic	<30 yr
COG APEC14B1	APEC14B1: The Project:Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study https://clinicaltrials.gov/ct2/show/NCT02402244	Non-therapeutic	≤25 yr
APEC1621SC	APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol https://clinicaltrials.gov/ct2/show/NCT03155620	NA	≥12 mo to ≤21 yr
COG ALTE03N1	Key Adverse Events after Childhood Cancer (cardiac,stroke,secondary malig)/ closed to AVN patients as of 11-26-08 https://clinicaltrials.gov/ct2/show/NCT00082745	Non-therapeutic	≤21 yr at dx
COG ALTE05N1	Umbrella Long-Term Follow-Up Protocol https://clinicaltrials.gov/ct2/show/NCT00736749	Non-therapeutic	All ages
QOL Targeted Tx Brain Tumors	Health-related Quality of Life Outcomes during Molecularly Targeted Therapy for the Treatment of High Risk Pediatric Brain Tumors	Non-therapeutic	≤21 yr
NF1 Frameshift	Frameshift Peptides of Children with Neurofibromatosis Type 1 (NF1) and either Low-grade Gliomas or Plexiform Neurofibromas https://clinicaltrials.gov/ct2/show/NCT04212351	Non-therapeutic	≥1 day to ≤30 yr
Telehealth Home-based Transition	Development and Pilot of a Telehealth Home-based Transition Intervention for Pediatric and Young Adults with Cancer	Non-therapeutic	≤29 yr
Medulloblastoma/PNET treatment protocols			
Study	**Clinical trial name**	**Phase/type**	**Age**
HEAD START 4	HEAD START 4 PROTOCOL: Newly Diagnosed Children (Less Than 10 Years Old) With Medulloblastoma And Other Central Nervous System Embryonal Tumors. Clinical And Molecular Risk-Tailored Intensive And Compressed Induction Chemotherapy Followed By Consolidation With Randomization To Either Single-Cycle Or To Three Tandem Cycles Of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue https://clinicaltrials.gov/ct2/show/NCT02875314	IV	<10 yr
Indoximod GCC1949	GCC1949: Phase 2 trial of indoximod with chemotherapy and radiation for children with progressive brain tumors or newly diagnosed DIPG https://clinicaltrials.gov/ct2/show/NCT04049669	II	>3 to <22 yr

AflacST1502 CHOANOME II	AflacST1502: A Phase II Study of Sirolimus in Combination with Metronomic Chemo-therapy in Children with Recurrent and/or Refractory Solid and CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02574728	II	>12 mo to ≤30 yr
COG ACNS1422[REQ]	ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-driven Medulloblastoma Patients https://clinicaltrials.gov/ct2/show/NCT02724579	II	≥3 yr to <22 yr
COG ADVL1823	ADVL1823, Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias https://clinicaltrials.gov/ct2/show/NCT03834961	II	≤30 yr
COG APEC1621A[REQ]	APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions https://clinicaltrials.gov/ct2/show/NCT03213704	II	≥12 mo to ≤21 yr
COG APEC1621B[REQ]	APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Relapsed Pediatric Solid Tumors Harboring FGFR1/2/3/4 Alterations https://clinicaltrials.gov/ct2/show/NCT03210714	II	≥12 mo to ≤21 yr
COG APEC1621C[REQ]	APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex https://clinicaltrials.gov/ct2/show/NCT03213665	II	≥12 mo to ≤21 yr
COG APEC1621D[REQ]	APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03213678	II	≥12 mo to ≤21 yr
COG APEC1621F[REQ]	APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations https://clinicaltrials.gov/ct2/show/NCT03213652	II	≥12 mo to ≤21 yr
COG APEC1621G[REQ]	APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Actionable BRAF V600 Mutations https://clinicaltrials.gov/ct2/show/NCT03220035	II	≥12 mo to ≤21 yr
COG APEC1621H[REQ]	APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes https://clinicaltrials.gov/ct2/show/NCT03233204	II	≥12 mo to ≤21 yr

COG APEC1621I[REQ]	APEC1621I NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes https://clinicaltrials.gov/ct2/show/NCT03526250	II	≥12 mo to ≤21 yr
COG APEC1621J[REQ]	APEC1621J NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations https://clinicaltrials.gov/ct2/show/NCT03698994	II	≥12 mo to ≤21 yr
Ignyta RXDX-101-03	A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02650401	I/Ib	≥2 to <22 yr
PBTC-053	A Pediatric Brain Tumor Consortium Phase I/II and Surgical Study of CX-4945 in Patients with Recurrent SHH Medulloblastoma https://clinicaltrials.gov/ct2/show/NCT03904862	I/II	≥3 to ≤18 yr
LOXO-EXT-17005	LOXO-EXT-17005: A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers https://clinicaltrials.gov/ct2/show/NCT03215511	I/II	≥1 mo
COG ADVL1514	ADVL1514, A Phase 1 Study of ABI-009 (Nab-Rapamycin) (IND# 133537) in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan https://clinicaltrials.gov/ct2/show/NCT02975882	I	≥12 mo to ≤21 yr
COG ADVL1615	ADVL1615, A Phase 1 Study of Pevonedistat (MLN4924 IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03323034	I	Part A1: ≥12 mo to ≤21 yr Part A2: ≥6 mo to <12 mo
COG ADVL1921	Phase 1 Study to Evaluate the Safety and Phrmacokinetics of Palbociclib (Ibrance®) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03709680	I	≥2 to <21 yr
AflacST1501	Aflac ST1501, A Phase I Study of Abemaciclib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and in Children with Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors https://clinicaltrials.gov/ct2/show/NCT02644460	I	≥2 to ≤25 yr
PBTC-045	PBTC-045: A Safety and Preliminary Efficacy trial of MK-3475 (pembrolizumab; anti-PD-1) in Children with	I	≥1 to ≤18 yr

	Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-brainstem High-grade Gliomas (NB-HGG), Ependymoma, Medullo-blastoma and Hypermutated Brain Tumors https://clinicaltrials.gov/ct2/show/NCT02359565		
PBTC-051	Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/ Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma https://clinicaltrials.gov/ct2/show/NCT03389802	I	≥1 to ≤21 yr
Medulloblastoma supportive treatment and non-therapeutic protocols			
Study	**Clinical trial name**	**Phase/type**	**Age**
AflacPM1702	Aflac Precision Medicine Program (APMP) Study	Non-therapeutic	<30 yr
COG APEC14B1	APEC14B1: The Project:Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study https://clinicaltrials.gov/ct2/show/NCT02402244	Non-therapeutic	≤25 yr
APEC1621SC	APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol https://clinicaltrials.gov/ct2/show/NCT03155620	NA	≥12 mo to ≤21 yr
COG ALTE03N1	Key Adverse Events after Childhood Cancer (cardiac, stroke, secondary malig)/closed to AVN patients as of 11-26-08 https://clinicaltrials.gov/ct2/show/NCT00082745	Non-therapeutic	≤21 yr at dx
COG ALTE05N1	Umbrella Long-Term Follow-Up Protocol https://clinicaltrials.gov/ct2/show/NCT00736749	Non-therapeutic	All ages
COG ALTE07C1	Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer	Non-therapeutic	3 to <22 yr
QOL Targeted Tx Brain Tumors	Health-related Quality of Life Outcomes during Molecularly Targeted Therapy for the Treatment of High-Risk Pediatric Brain Tumors	Non-therapeutic	≤21 yr
CTCCs for MB	Circulating Tumor Cell Clusters as a Novel Biomarker for Medulloblastoma Treatment (CTCCs for MB)	Biology	≤21 yr
Telehealth Home-based Transition	Development and Pilot of a Telehealth Home-based Transition Intervention for Pediatric and Young Adults with Cancer	Non-therapeutic	≤29 yr

Other brain tumor treatment protocols (includes atypical teratoid/rhabdoid tumors, optic pathway, pilocytic astrocytoma)			
Study	**Clinical trial name**	**Phase/type**	**Age**
Indoximod GCC1949	GCC1949: Phase 2 trial of indoximod with chemotherapy and radiation for children with progressive brain tumors or newly diagnosed DIPG https://clinicaltrials.gov/ct2/show/NCT04049669	II	>3 to <22 yr
AflacST1502 CHOANOME II	AflacST1502: A Phase II Study of Sirolimus in Combination with Metronomic Chemo-therapy in Children with Recurrent and/or Refractory Solid and CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02574728	II	>12 mo to ≤30 yr
SJATRT	Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed AT/RT (SJATRT)	II	<22 yr
COG ADVL1823	ADVL1823, Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias https://clinicaltrials.gov/ct2/show/NCT03834961	II	≤30 yr
COG APEC1621A[REQ]	APEC1621A: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions https://clinicaltrials.gov/ct2/show/NCT03213704	II	≥12 mo to ≤21 yr
COG APEC1621B[REQ]	APEC1621B: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Relapsed Pediatric Solid Tumors Harboring FGFR1/2/3/4 Alterations https://clinicaltrials.gov/ct2/show/NCT03210714	II	≥12 mo to ≤21 yr
COG APEC1621C[REQ]	APEC1621C: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex https://clinicaltrials.gov/ct2/show/NCT03213665	II	≥12 mo to ≤21 yr
COG APEC1621D[REQ]	APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03213678	II	≥12 mo to ≤21 yr
COG APEC1621F[REQ]	APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations https://clinicaltrials.gov/ct2/show/NCT03213652	II	≥12 mo to ≤21 yr

COG APEC1621G[REQ]	APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) – Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Actionable BRAF V600 Mutations https://clinicaltrials.gov/ct2/show/NCT03220035	II	≥12 mo to ≤21 yr
COG APEC1621H[REQ]	APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes https://clinicaltrials.gov/ct2/show/NCT03233204	II	≥12 mo to ≤21 yr
COG APEC1621I[REQ]	APEC1621I NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes https://clinicaltrials.gov/ct2/show/NCT03526250	II	≥12 mo to ≤21 yr
COG APEC1621J[REQ]	APEC1621J NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations https://clinicaltrials.gov/ct2/show/NCT03698994	II	≥12 mo to ≤21 yr
COG APEC1621K[REQ]	APEC1621K NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)—Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations https://clinicaltrials.gov/ct2/show/NCT04195555	II	≥12 mo to ≤21 yr
Ignyta RXDX-101-03	A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors https://clinicaltrials.gov/ct2/show/NCT02650401	I/Ib	≥2 to <22 yr
LOXO-EXT-17005	LOXO-EXT-17005: A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers https://clinicaltrials.gov/ct2/show/NCT03215511	I/II	≥1 mo
AflacST1501	Aflac ST1501, A Phase I Study of Abemaciclib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma and in Children with Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors https://clinicaltrials.gov/ct2/show/NCT02644460	I	≥2 to ≤25 yr
PBTC-045	PBTC-045: A Safety and Preliminary Efficacy trial of MK-3475 (pembrolizumab; anti-PD-1) in Children with Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-brainstem High-grade Gliomas (NB-HGG), Ependymoma, Medullo-blastoma and Hypermutated Brain Tumors https://clinicaltrials.gov/ct2/show/NCT02359565	I	≥1 to ≤18 yr

COG ADVL1615	ADVL1615, A Phase 1 Study of Pevonedistat (MLN4924 IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03323034	I	Part A1: ≥12 mo to ≤21 yr Part A2: ≥6 mo to <12 mo
COG ADVL1921	Phase 1 Study to Evaluate the Safety and Phrmacokinetics of Palbociclib (Ibrance®) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors https://clinicaltrials.gov/ct2/show/NCT03709680	I	≥2 to <21 yr
EZH-102	A Phase I Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma	I	≥6 mo to ≤21 yr
PBTC-051	Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/ Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma https://clinicaltrials.gov/ct2/show/NCT03389802	I	≥1 to ≤21 yr

Other brain tumor supportive treatment and non-therapeutic protocols			
Study	**Clinical trial name**	**Phase/type**	**Age**
AflacPM1702	Aflac Precision Medicine Program (APMP) Study	Non-therapeutic	<30 yr
COG APEC14B1	APEC14B1: The Project:Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study https://clinicaltrials.gov/ct2/show/NCT02402244	Non-therapeutic	≤25 yr
APEC1621SC	APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol https://clinicaltrials.gov/ct2/show/NCT03155620	NA	≥12 mo to ≤21 yr
COG ALTE03N1	Key Adverse Events after Childhood Cancer (cardiac, stroke, secondary malig)/closed to AVN patients as of 11-26-08 https://clinicaltrials.gov/ct2/show/NCT00082745	Non-therapeutic	≤21 yr at dx
COG ALTE05N1	Umbrella Long-Term Follow-Up Protocol https://clinicaltrials.gov/ct2/show/NCT00736749	Non-therapeutic	All ages
QOL Targeted Tx Brain Tumors	Health-related Quality of Life Outcomes during Molecularly Targeted Therapy for the Treatment of High Risk Pediatric Brain Tumors	Non-therapeutic	≤21 yr
Telehealth Home-based Transition	Development and Pilot of a Telehealth Home-based Transition Intervention for Pediatric and Young Adults with Cancer	Non-therapeutic	≤29 yr